Warner Chilcott's term loan "B" dropped under par on news it is being sued by the U.S. Federal Trade Commission for blocking generic production of an oral contraceptive. Its term loan "B" fell to 99 7/8 from 100 1/8. Warner Chilcott, a pharmaceutical company, reportedly paid another drug company, Barr Pharacueticals, $20 million to prevent Barr's generic Ovcon from entering the U.S. market until May 2009. The suit filed in the U.S. District Court for the District of Columbia seeks to stop the provision barring the generic version from the U.S. market. Twenty-one states and the District of Columbia are reportedly seeking civil penalties. Warner Chilcott officials could not be reached by press time.
Want full access to GlobalCapital?
If you are new to GlobalCapital or you already subscribe to some of our channels you can still easily extend your access.
Take a trial to the entire site or subscribe online to see all our capital markets news, opinion and data sets.
Don't miss out!Free trial
Read the magazine on your mobile device
Most Viewed: Securitization
Latest news by market and league table performance
|Rank||Lead Manager/Arranger||Total Volume $m||No. of Deals||Share % by Volume|
|5||Bank of America Merrill Lynch (BAML)||2,086||9||7.98|
Bookrunners of Global Structured Finance
|Rank||Lead Manager||Amount $m||No of issues||Share %|
|3||Bank of America Merrill Lynch||41,109.55||134||7.53%|
|4||Wells Fargo Securities||40,627.46||119||7.45%|